Sign in

    Rajan Sharma • Goldman Sachs

    Rajan Sharma's questions to Valneva SE (VALN) leadership

    Rajan Sharma's questions to Valneva SE (VALN) leadership • Q2 2025

    Question

    Rajan Sharma from Goldman Sachs questioned the 2025 timeline for the Lyme vaccine Phase 3 data given a later date on clinicaltrials.gov, and asked about the efficacy bar for success and FDA approvability compared to previous vaccines.

    Answer

    CEO Thomas Lingelbach clarified that the clinicaltrials.gov date includes longer safety follow-up periods and that Pfizer's reaffirmed 2026 submission timeline is the key metric. He stated there is no pre-aligned efficacy bar with the FDA, but precedents exist. He emphasized that direct comparisons to older vaccines are difficult due to different trial designs and that the primary endpoint was strategically set after the full 3+1 dose schedule.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to Valneva SE (VALN) leadership • Q1 2025

    Question

    Rajan Sharma from Goldman Sachs inquired about the timing and triggers for the $143 million milestone payment from Pfizer for the Lyme vaccine and asked for Valneva's perspective on the potential impact of tariffs on its manufacturing operations.

    Answer

    CFO Peter Buhler clarified that the $143 million milestone is tied to the first commercialization of the Lyme vaccine, expected in 2027, and is triggered by first sales in the U.S. and Europe, plus an ACIP opinion. He also noted further commercial milestones and royalties. Regarding tariffs, Mr. Buhler stated it is too early to assess the impact but confirmed Valneva's vaccines are manufactured in Europe (Scotland, Germany, and Sweden), which they are monitoring closely.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to Genmab A/S (GMAB) leadership

    Rajan Sharma's questions to Genmab A/S (GMAB) leadership • Q2 2025

    Question

    Rajan Sharma of Goldman Sachs asked about the launch strategy for Epkinley in second-line follicular lymphoma, whether its label would require hospitalization, and the rationale for discontinuing the Hexabody OX40 program.

    Answer

    Chief Commercial Officer Brad Bailey outlined the launch strategy, focusing on expanding into the community setting. Chief Medical Officer Tahamtan Ahmadi confirmed the label would not require hospitalization and explained the OX40 discontinuation was a portfolio prioritization decision, not a failure of the Hexabody platform. CEO Jan van de Winkel reinforced confidence in the platform.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to Genmab A/S (GMAB) leadership • Q1 2025

    Question

    Rajan Sharma of Goldman Sachs asked to reconcile a discrepancy between the company's guided 2026 readout for the EPCORE DLBCL-2 trial and the mid-2027 date listed on clinicaltrials.gov.

    Answer

    CMO Tahamtan Ahmadi advised that clinicaltrials.gov is not always the most updated source for timelines. He explained that trial readouts are event-driven and accrual for this specific study was significantly faster than projected, potentially leading to an earlier result than the official registry date suggests.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to Immunocore Holdings PLC (IMCR) leadership

    Rajan Sharma's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2025

    Question

    Rajan Sharma of Goldman Sachs asked about the company's confidence in having sufficient U.S. trial sites and representative patient demographics for the TEBY-AM and ATOM trials to satisfy the FDA. He also inquired about Chemtrac's penetration in Europe versus the U.S.

    Answer

    David Berman, EVP of R&D, expressed confidence, stating they have enough U.S. sites and that most international sites are in regions with the same standard of care. Ralph Torbay, EVP of Commercial, noted that penetration in mature European markets like Germany and France is over 80%, which serves as a guide for the potential in the U.S. as they continue to penetrate the community setting.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to Immunocore Holdings PLC (IMCR) leadership • Q4 2024

    Question

    Rajan Sharma of Goldman Sachs asked about long-term benchmarks for the atopic dermatitis program and whether the upcoming HIV data could provide a positive cross-read to the HBV program and the platform's broader potential.

    Answer

    David Berman, Head of R&D, said that for atopic dermatitis, the initial focus is on refractory patients to establish a signal before defining a commercial TPP. He views the HIV and HBV data as a package that will be important for validating the ImmTAV platform in chronic viral diseases. CEO Bahija Jallal added that the CD1a target in atopic dermatitis has potential across multiple indications.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2024

    Question

    Rajan Sharma from Goldman Sachs asked about the long-term pricing evolution for KIMMTRAK with new indications, whether folate receptor alpha positive patients are included in the ovarian trial, and the potential maximum dose for the HIV program.

    Answer

    Ralph Torbay, Head of Commercial, expects minimal U.S. price erosion but noted European viability depends on future data. Mohammed Dar, an executive, confirmed folate receptor alpha patients are included and that the HIV program likely won't require high milligram doses, as the platform is potent at microgram levels.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2024

    Question

    Rajan Sharma from Goldman Sachs asked about the long-term pricing evolution for KIMMTRAK with potential label expansions, whether folate receptor alpha positive patients are included in the ovarian trial, and the potential maximum dose in the HIV trial.

    Answer

    Ralph Torbay, Head of Commercial, said pricing depends on the benefit shown and expects no significant U.S. price erosion, though Europe is challenging. Mohammed Dar, an executive, confirmed they don't exclude prior folate receptor alpha patients. Regarding the HIV trial, he stated that while the maximum dose is unknown, their platform generally does not require high doses to be effective.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to argenx SE (ARGX) leadership

    Rajan Sharma's questions to argenx SE (ARGX) leadership • Q2 2025

    Question

    Speaking for Rajan Sharma from Goldman Sachs, an analyst asked if the near doubling of global CIDP patients on Vyvgart (to 2,500) between January and June 2025 serves as a reliable proxy for the growth rate for the remainder of the year.

    Answer

    COO Karen Massey confirmed the 2,500 global patient number reflects strong momentum that is expected to continue. She highlighted that this figure includes fast starts in newly launched markets like Japan and Germany, demonstrating a significant unmet need for innovation in CIDP globally, which supports continued growth.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to argenx SE (ARGX) leadership • Q1 2025

    Question

    Rajan Sharma asked for clarification on the relative magnitude of the headwinds to Q1 revenue growth, specifically between typical seasonality (reverification) and the impact from the Medicare redesign.

    Answer

    Chief Financial Officer Karl Gubitz explained that while the Medicare redesign accelerated the shift to Part D and increased the gross-to-net, the majority of the Q1 impact was due to typical industry seasonality related to patient benefit reverification. Chief Operating Officer Karen Massey reinforced this, noting the dynamic was similar to the previous year and that the company expects continued growth throughout the year, driven by the PFS launch.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to argenx SE (ARGX) leadership • Q4 2024

    Question

    Rajan Sharma asked for an update on the myasthenia gravis (MG) market expansion, specifically how much of the potential 25,000-patient market growth has been realized since the 2021 launch.

    Answer

    Chief Operating Officer Karen Massey responded that while market expansion is occurring, they are still in the early stages of the growth curve. She cited the fact that 60% of new VYVGART patients come directly from oral therapies as evidence of penetrating this expanded market, but believes there is still a long way to go.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to argenx SE (ARGX) leadership • Q1 2024

    Question

    Rajan Sharma inquired about the regulatory steps, timeline, and potential for a faster review process for the VYVGART prefilled syringe (PFS) following recent data collection.

    Answer

    CEO Tim Van Hauwermeiren confirmed that Argenx has successfully collected all necessary bioequivalence and human factors study data for the PFS. He stated the company is on track to submit the dossier to the FDA by the end of June, expressing confidence in the data's quality while noting the final review timeline is at the FDA's discretion.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to GSK plc (GSK) leadership

    Rajan Sharma's questions to GSK plc (GSK) leadership • Q2 2025

    Question

    Rajan Sharma requested an update on the launch timeline for Bligepa (Bluejepa) and its expected trajectory, and also asked for the key drivers behind the company's increased R&D expense guidance.

    Answer

    CFO Julie Brown attributed the higher R&D spend to accelerating the ADC portfolio, particularly B7-H3, and funding four new pivotal trials in H2. CCO Luke Miels stated the Bligepa launch is set for later in the year with a full push in Q1 2026 to align with payer formulary timing, targeting a population of 3 million patients with resistant UTIs.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to GSK plc (GSK) leadership • Q1 2025

    Question

    Rajan Sharma inquired about potential REMS requirements for Blenrep and their influence on uptake, and asked if lower market valuations might spur more business development activity.

    Answer

    CEO Emma Walmsley confirmed that BD remains a high priority. CSO Tony Wood noted that REMS are common in oncology and the U.K. approval provides a potential model. CCO Luke Miels added that the launch strategy is built around supporting physicians in managing Blenrep's known side effects, leveraging collaborations with eye care professionals to ensure a smooth process.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to GSK plc (GSK) leadership • Q4 2024

    Question

    Rajan Sharma of Goldman Sachs asked about the drivers of the positive channel mix in HIV and its sustainability, and sought to reconcile the £2B uplift in 2031 guidance with Blenrep's £3B peak sales potential, also asking about the key differences versus consensus estimates.

    Answer

    CEO Emma Walmsley reiterated the 'more than £40 billion' 2031 outlook and confirmed no change to Blenrep's peak sales ambition. Chief Financial and Administrative Officer David Redfern noted the main channel mix headwind in HIV is the rise of 340B, but other trends are stable. CFO Julie Brown explained the guidance delta versus consensus is primarily in Oncology (Blenrep, Jemperli) and RI&I (camlipixant, depemokimab), where the market is likely awaiting further data and launch traction.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to AstraZeneca PLC (AZN) leadership

    Rajan Sharma's questions to AstraZeneca PLC (AZN) leadership • Q2 2025

    Question

    Rajan Sharma of Goldman Sachs asked for the target profile of asfotase alfa (Amphicosalpha) and the residual unmet need it aims to address in the context of the existing therapy, Strensiq.

    Answer

    CEO of Alexion, Marc Dunoyer, explained that asfotase alfa is being developed for both adult and pediatric populations with a goal of wider geographic coverage than Strensiq. He highlighted a key patient benefit: a less frequent dosing schedule of one injection every two weeks, compared to six or twelve for Strensiq in the same period. He noted Phase 3 results are expected by year-end.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to AstraZeneca PLC (AZN) leadership • Q1 2025

    Question

    Rajan Sharma asked about the potential filing strategy for the DESTINY-Breast09 (DB09) combination therapy and sought clarification on whether overall survival data from the TROPION-Lung01 QCS biomarker analysis would be presented at ASCO.

    Answer

    EVP, Oncology R&D, Susan Galbraith stated that discussions with regulators regarding the DB09 filing are ongoing, noting the data's "highly clinically meaningful results" will be influential. She clarified that the upcoming ASCO presentation will feature a QCS biomarker analysis from the TROPION-Lung02 dataset, not TROPION-Lung01, which will provide additional supportive evidence for the biomarker's utility.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to AstraZeneca PLC (AZN) leadership • Q4 2024

    Question

    Rajan Sharma from Goldman Sachs asked if a cardiovascular outcomes trial is necessary for meaningful uptake of the oral PCSK9 inhibitor and whether a positive PFS result from the AVANZAR trial would be sufficient for a conditional approval in lung cancer.

    Answer

    Sharon Barr, EVP of BioPharmaceuticals R&D, deferred comment on specific outcomes trial plans for the oral PCSK9, noting it's still early in development. Susan Galbraith, EVP of Oncology R&D, explained that for a first-line lung cancer filing based on PFS, regulatory agencies generally also want to see a positive trend in overall survival and reasonable data maturity.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to AstraZeneca PLC (AZN) leadership • Q2 2024

    Question

    Rajan Sharma inquired about the implications of recent competitor data for Wainua's CARDIO-TTRansform trial and asked about the market dynamics and patient sources for Ultomiris in myasthenia gravis.

    Answer

    EVP, BioPharmaceuticals R&D, Sharon Barr, said that positive competitor data validates the drug's mechanism, increasing confidence in the ongoing CARDIO-TTRansform study. EVP, Rare Disease, Marc Dunoyer, explained that the myasthenia gravis market is highly dynamic and that Ultomiris's strong 36% growth was driven predominantly by its neurology indications, a trend he expects to continue.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to Zealand Pharma A/S (ZLDPF) leadership

    Rajan Sharma's questions to Zealand Pharma A/S (ZLDPF) leadership • Q3 2024

    Question

    Rajan Sharma inquired about the go-to-market strategy for glepaglutide if launched without a partner, the necessity of a head-to-head trial for petrelintide, and whether a gender-based difference in weight loss was observed in the petrelintide trial.

    Answer

    CEO Adam Steensberg, CCO Eric Cox, and CMO David Kendall addressed the questions. Mr. Cox outlined a focused, rare-disease commercial model for a potential solo glepaglutide launch while partnership talks continue. Mr. Cox and Dr. Kendall agreed a head-to-head trial for petrelintide would be important for differentiation, with timing to be determined post-Phase II. Mr. Steensberg confirmed that while detailed data is pending, they anticipate females will show greater weight loss, consistent with other obesity drugs.

    Ask Fintool Equity Research AI

    Rajan Sharma's questions to Zealand Pharma A/S (ZLDPF) leadership • Q3 2024

    Question

    Rajan Sharma of Goldman Sachs inquired about the potential go-to-market strategy for glepaglutide if launched without a partner, including expected SG&A costs. He also asked if a head-to-head trial against GLP-1s is necessary for petrelintide to become a foundational therapy, and if there was a gender-based difference in weight loss in the Phase Ib data.

    Answer

    President and CEO Adam Steensberg noted that detailed gender-split data for petrelintide was not yet public but expects females to show greater weight loss. Chief Commercial Officer Eric Cox explained that an initial glepaglutide launch would have a focused footprint with a modest SG&A increase, while they actively seek a partner. He and Chief Medical Officer David Kendall confirmed a head-to-head trial for petrelintide is under consideration for Phase III or IIIb, pending dose finalization from the Phase IIb study.

    Ask Fintool Equity Research AI